Body iron homeostasis can only be regulated through balance of dietary iron, chelating it to proteins, or by storing it in RES organs (bone marrow, spleen, and liver). For this reason, chelators (whether i.v. or oral) must rely on renal clearance and fecal elimination to remove excess iron from the body. The significance of this proposal could be wide-ranging for a variety of diseases that relies on chelation therapy to alleviate symptoms of metal overload, since small molecule metal chelators have traditionally suffered from a short residence time in the body and unspecific organ targeting. In this proposal, we will specifically investigate nanoparticles for chelation of transfusional iron overload. Surprisingly, there are only three FDA-approved small molecule chelators available for treating iron overload and there is a need for new and improved technology. In order to achieve a sufficient window of therapy, a balance between renal clearance and pharmacokinetics should be achieved, which current small molecule chelators currently lack. Nanotechnology has already dramatically demonstrated that it can be used to improve the pharmacokinetics of small molecule drugs, with enhanced efficacy and specificity of therapies through the use of targeting ligands. We are the first lab, to the best of our knowledge, to investigate novel designs of nanoparticles we call """"""""lipoGels"""""""" for chelation of iron. LipoGels can pick up both forms of iron, Fe2+ and Fe3+, which is critical for iron chelation therapy. Another unique aspect of our innovative technology is that lipoGels can be consistently fabricated and tailored to desired in vivo behavior. Advantages include prolonged circulation, lower doses, and targeting via ligands to organs as desired, while attempting to balance renal and fecal elimination of iron-bound degradation products. We believe that this is an exciting project with potential to push the field of chelation therapy forward.
The aims i n this proposal are to 1) systematically prepare and characterize lipoGels for in vivo chelation of iron, 2) investigate the mechanism of iron chelation in vitro, and maximum tolerated dose, pharmacokinetics, and biocompatibility/safety of lipoGels in vivo, and 3) test the iron chelation efficacy of optimized lipoGels in rat models of iron overload.

Public Health Relevance

In this proposal, we will investigate nanoparticles for chelation of transfusional iron overload. LipoGels can pick up both forms of iron, Fe2+ and Fe3+, which is critical for iron chelation therapy. Nanoparticles can be consistently fabricated and tailored t desired in vivo behavior. Advantages include prolonged circulation, lower doses, and targeting via ligands to organs as desired, while attempting to balance renal and fecal elimination of iron-bound degradation products.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
1R01DK099596-01
Application #
8562927
Study Section
Nanotechnology Study Section (NANO)
Program Officer
Bishop, Terry Rogers
Project Start
2013-06-15
Project End
2018-05-31
Budget Start
2013-06-15
Budget End
2014-05-31
Support Year
1
Fiscal Year
2013
Total Cost
$285,817
Indirect Cost
$90,067
Name
University of Wisconsin Madison
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Liu, Zhi; Qiao, Jing; Nagy, Tamas et al. (2018) ROS-triggered degradable iron-chelating nanogels: Safely improving iron elimination in vivo. J Control Release 283:84-93
Simchick, Gregory; Liu, Zhi; Nagy, Tamas et al. (2018) Assessment of MR-based R2* and quantitative susceptibility mapping for the quantification of liver iron concentration in a mouse model at 7T. Magn Reson Med 80:2081-2093
Qiao, Jing; Purro, Max; Liu, Zhi et al. (2018) Terpyridine-Micelles for Inhibiting Bacterial Biofilm Development. ACS Infect Dis 4:1346-1354
Wang, Yan; Liu, Zhi; Lin, Tien-Min et al. (2018) Nanogel-DFO conjugates as a model to investigate pharmacokinetics, biodistribution, and iron chelation in vivo. Int J Pharm 538:79-86
Qiao, Jing; Liu, Zhi; Purro, Max et al. (2018) Antibacterial and Potentiation Properties of Charge-Optimized Polyrotaxanes for Combating Opportunistic Bacteria. J Mater Chem B 6:5353-5361
Liu, Zhi; Purro, Max; Qiao, Jing et al. (2017) Multifunctional Polymeric Micelles for Combining Chelation and Detection of Iron in Living Cells. Adv Healthc Mater 6:
Liu, Zhi; Wang, Yan; Purro, Max et al. (2016) Oxidation-Induced Degradable Nanogels for Iron Chelation. Sci Rep 6:20923
Kapur, Arvinder; Felder, Mildred; Fass, Lucas et al. (2016) Modulation of oxidative stress and subsequent induction of apoptosis and endoplasmic reticulum stress allows citral to decrease cancer cell proliferation. Sci Rep 6:27530
Liu, Zhi; Lin, Tien-Min; Purro, Max et al. (2016) Enzymatically Biodegradable Polyrotaxane-Deferoxamine Conjugates for Iron Chelation. ACS Appl Mater Interfaces 8:25788-25797
Zeng, San; Kapur, Arvinder; Patankar, Manish S et al. (2015) Formulation, Characterization, and Antitumor Properties of Trans- and Cis-Citral in the 4T1 Breast Cancer Xenograft Mouse Model. Pharm Res 32:2548-58

Showing the most recent 10 out of 12 publications